Storia in 3 fonti

Lupin spins out two cancer drug programmes to new US venture for $1.6 million stake

Lupin licenses two cancer drug programs to Kaveri Therapeutics for an $1.6 million stake, enhancing its oncology portfolio.

Raccontata da

Confronto fonti

3 prospettive sulla stessa storia

AI · summaries

Lupin licenses two cancer drug programs to Kaveri Therapeutics for an $1.6 million stake, enhancing its oncology portfolio.

Lupin acquires 82.2% stake in Kaveri Therapeutics, licensing two oncology assets for $1.6 million to enhance clinical trials.